Table 5 Cost-effectiveness of screening compared to no screening under various survival scenarios
Scenario: | Conservative survivala | Balanced survivala | Optimistic survivala |
|---|---|---|---|
Model parameter: | Â | Â | Â |
   % surviving to age 16 | 90% | 95% | 97% |
   % surviving to age 30 | 72% | 84% | 90% |
   % surviving to age 50 | 30% | 45% | 55% |
   Median survival (years) | 41 | 48 | 52 |
   Mean survival (years) | 39.4 | 45.8 | 49.9 |
Mean years spent: | Â | Â | Â |
   before symptoms emerge | 1.0 | 1.0 | 1.0 |
   with symptoms | 32.3 | 38.7 | 42.8 |
   in severe irreversible stage | 6.1 | 6.1 | 6.1 |
Incremental C/E ratio (£/QALY) | £7,474 | £6,864 | £6,532 |